✦ LIBER ✦

Optimal treatment duration for patients with HCV genotype 1 infection

✍ Scribed by P. Ferenci

Book ID: 108886658
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 94 KB
Volume: 19
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2011.01522.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Individualized treatment duration for he

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

✍ Alessandra Mangia; Nicola Minerva; Donato Bacca; Raffaele Cozzolongo; Giovanni L 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 269 KB 👁 2 views

It was hypothesized that in hepatitis C virus (HCV) genotype 1 patients, variable treatment duration individualized by first undetectable HCV RNA is as effective as standard 48-week treatment. Patients (n = 696) received peginterferon alfa-2a, 180 mg/week, or peginterferon alfa-2b, 1.5 mg/kg/week, p

Leucoytapheresis with Adacolumn® enhance

Leucoytapheresis with Adacolumn® enhances HCV-specific proliferative responses in patients infected with hepatitis C virus genotype 1

✍ Helmut M. Diepolder; Nobuhito Kashiwagi; Gerlinde Teuber; Axel Ulsenheimer; Mari 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 198 KB

IP-10 predicts viral response and therap

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection

✍ Martin Lagging; Ana I. Romero; Johan Westin; Gunnar Norkrans; Amar P. Dhillon; J 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 540 KB

Plasma from 173 patients with HCV genotype 1 infection was analyzed for IP-10 levels prior to treatment with pegylated interferon-␣-2a and ribavirin. Significantly lower IP-10 levels were observed in patients achieving a rapid viral response (RVR) (P < .0001), even in those with body mass index (BMI

Rapid virological response and treatment

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial

✍ Ming-Lung Yu; Chia-Yen Dai; Jee-Fu Huang; Chang-Fu Chiu; Yi-Hsin C. Yang; Nai-Je 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 310 KB 👁 1 views

Recommended treatment for hepatitis C virus genotype 1 (HCV-1) patients is peginterferon plus ribavirin for 48 weeks. We assessed whether treatment duration of 24 weeks is as effective as standard treatment in HCV-1 patients with a rapid virological response (RVR; seronegative for hepatitis C virus

Treatment with pegylated interferon and

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: A pilot study

✍ Olav Dalgard; Kristian Bjøro; Kjell Block Hellum; Bjørn Myrvang; Ståle Ritland; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

The aim of this study was to determine the efficacy of 14 weeks of treatment in patients infected with hepatitis C virus (HCV) genotype 2 or 3 who achieve early virological response (EVR). In a noncontrolled multicenter trial, 122 treatment-naive patients received 1.5 mug/kg pegylated interferon alf

IL28B alleles associated with poor hepat

IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes

✍ Pierre-Yves Bochud; Stéphanie Bibert; Zoltán Kutalik; Etienne Patin; Julien Guer 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 375 KB 👁 2 views

Poynard owns stock in Biopredictive. He also consults for and is on the speakers' bureau of Merck. Dr. Pol consults for, advises, and is on the speakers' bureau of Boehringer Ingleheim, Abbott, and GlaxoSmithKline. He consults for, advises, is on the speakers' bureau of, and received grants from Roc